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Abstract
Background Clinicians have questioned whether any disorder involving seizures and neural antibodies should be called 
“(auto)immune epilepsy.” The concept of “acute symptomatic seizures” may be more applicable in cases with antibod-
ies against neural cell surface antigens. We aimed at determining the probability of achieving seizure-freedom, the use of 
anti-seizure medication (ASM), and immunotherapy in patients with either constellation. As a potential pathophysiological 
correlate, we analyzed antibody titer courses.
Methods Retrospective cohort study of 39 patients with seizures and neural antibodies, follow-up ≥ 3 years.
Results Patients had surface antibodies against the N-methyl-d-aspartate receptor (NMDAR, n = 6), leucine-rich glioma 
inactivated protein 1 (LGI1, n = 11), contactin-associated protein-2 (CASPR2, n = 8), or antibodies against the intracellular 
antigens glutamic acid decarboxylase 65 kDa (GAD65, n = 13) or Ma2 (n = 1). Patients with surface antibodies reached 
first seizure-freedom (88% vs. 7%, P < 0.001) and terminal seizure-freedom (80% vs. 7%, P < 0.001) more frequently. The 
time to first and terminal seizure-freedom and the time to freedom from ASM were shorter in the surface antibody group 
(Kaplan–Meier curves: P < 0.0001 for first seizure-freedom; P < 0.0001 for terminal seizure-freedom; P = 0.0042 for terminal 
ASM-freedom). Maximum ASM defined daily doses were higher in the groups with intracellular antibodies. Seizure-freedom 
was achieved after additional immunotherapy, not always accompanied by increased ASM doses. Titers of surface antibodies 
but not intracellular antibodies decreased over time.
Conclusion Seizures with surface antibodies should mostly be considered acute symptomatic and transient and not indica-
tive of epilepsy. This has consequences for ASM prescription and social restrictions. Antibody titers correlate with clinical 
courses.
Keywords Autoimmune encephalitis · Neural antibodies · Acute symptomatic seizures · Epilepsy · Long-term course
Abbreviations
ASM  Anti-seizure medication
CASPR2  Contactin-associated protein-2
DDD  Defined daily doses
GAD65  Glutamic acid decarboxylase 65 kDa
HS  Hippocampal sclerosis
ILAE  International league against epilepsy
LGI1  Leucine-rich glioma inactivated protein 1
NMDAR  N-Methyl-d-aspartate receptor
IVMP  Intravenous methylprednisolone
Introduction
In its most recent classification paper, the International 
League Against Epilepsy (ILAE) introduced the new etio-
logical category of “immune epilepsy.” The ILAE herewith 
referred to the emerging group of autoimmune encepha-
litides and explicitly mentioned antibodies against the 
N-methyl-d-aspartate receptor (NMDAR) and leucine-rich 
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glioma inactivated protein 1 (LGI1) [40]. Autoimmune 
conditions with seizures have frequently been studied under 
the heading “autoimmune epilepsy” [3, 31, 39]. Recently, 
researchers [24] and the Autoimmunity/Inflammation Task 
Force [44] of the ILAE have suggested that patients with 
autoimmune encephalitides and pathogenic antibodies 
against cell surface antigens should be considered to have 
“seizures secondary to autoimmune encephalitis” in the 
sense of acute symptomatic seizures [1], should not regularly 
receive long-term anti-seizure medication (ASM), and be 
exempt from the social restrictions for epilepsy patients. In 
contrast, autoimmune-related seizures that recur in an unpro-
voked manner and are resistant to immunological therapy 
should be called “autoimmune-associated epilepsy.” These 
conditions are T cell-driven encephalitides [6], often with 
antibodies against intracellular antigens like glutamic acid 
decarboxylase 65 kDa (GAD65) [9], onconeural proteins 
[42] or Rasmussen encephalitis [50]. There are unfortunate 
cases with surface antibodies who also develop “autoim-
mune-associated epilepsy.” Geis and colleagues tentatively 
suggested one year as a cut-off between seizures secondary 
to autoimmune encephalitis and autoimmune epilepsy [24]; 
the ILAE task force felt that the database for such a bor-
der was still insufficient [44]. Here, we present long-term 
outcome data that support such a general distinction, but 
with a much longer time frame to become seizure-free for 




We included patients of any age if they: (1) harbored 
neural antibodies in serum or CSF (CSF antibodies were 
needed for the diagnosis of NMDAR antibodies [25], 
serum titers ≥ 1:128 were required for contactin-associ-
ated protein-2 (CASPR2) antibodies [4], and ≥ 1:1500 for 
GAD65 antibodies [15]); (2) had > 1 seizure; (3) a follow-up 
of ≥ 36 months; and (4) at least three antibody titers (serum 
or CSF).
CGB identified the patients from the databases of the 
Bethel Antibody Laboratory and the Laboratory Krone 
(2011–2019). The treating physicians offered repeated 
consultations and examinations, including antibody tests 
for clinical reasons and the patients utilized these services. 
The responsible physicians retrospectively collected clini-
cal information. AR and CGB extracted the following data: 
seizure frequency or occurrence of seizures (yes/no); ASM 
defined daily doses (DDD); time to antibody diagnosis and 
time to start of immunotherapy; types and numbers of immu-
notherapies and their duration. AR and CGB rated clinical 
performance by consensus according to the modified Rankin 
Scale (mRS) [26]. Values ≤ 2 indicate independent living of 
the patient and values > 2 increasing degrees of dependency. 
“Seizure-freedom” and “ASM-freedom” required this status 
for ≥ 12 months. We only counted clinical seizures.
Methods
Antibodies and their titers (multiples of 1:2) were deter-
mined in the Bethel Antibody Laboratory and (since 2016) 
in the Laboratory Krone, as described previously [2, 4]. Ma2 
titers were determined with the tissue-based assay [2, 4].
Graphs and statistics
Demographic data are presented in Fig. 1. For group-wise 
comparisons, we used the Mann–Whitney U test or the two-
tailed Fisher’s exact test (Prism, version 6, GraphPad Soft-
ware Inc., San Diego, CA). We depicted the times to seizure 
and ASM-freedom using Kaplan–Meier curves (Fig. 2) and 
analyzed the differences with Mantel–Cox log-rank tests 
(Prism). For each patient, we prepared diagrams for the fol-
lowing parameters: seizures, ASM, mRS, immunotherapies, 
and antibody titers in serum and CSF; they are shown in the 
Supplementary Figure.
We preliminarily set the significance level to P < 0.05 
and used Bonferroni correction for 11 tests. Thus, the sig-
nificance level was P < 0.0045. We averaged antibody titers 
(expressed as the percent of the individual’s highest recorded 
titer) using 15 neighboring points with a second order poly-
nomial smoothing (Prism), see Fig. 3.
Ethics
This study was approved by the Ethics Committee of the 
University of Münster, Germany (2018–436-f-S). Since this 
was a retrospective analysis of data from the authors’ own 
clinical practice, patients’ consent was not required.
Results
We included 39 patients. The median disease duration from 
disease manifestation to most recent follow-up was 7.5 years 
(range 3.0–35.1), and the median time from antibody detec-
tion to most recent follow-up was 6.4 years (3.0–13.9 years). 
The patients harbored antibodies directed against the follow-
ing antigens: NMDAR, n = 6; LGI1, n = 11; CASPR2, n = 8 
(cell surface antigens); GAD65, n = 13; Ma2, n = 1 (intracel-
lular antigens). The patients’ characteristics are shown in 
Fig. 1 and Table 1; individual data and information, which 
patients had been included in previous studies [2, 4–6, 15, 
36, 41] are given in Supplementary Table 1.
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Demographics were similar to previous publications 
on surface [10], GAD65 [38], and Ma2 [11] antibodies. 
All patients with surface antibodies (apart from patient 
CASPR2-2) had definite autoimmune encephalitides 
according to recent diagnostic criteria [25], either in the 
form of definite limbic encephalitis [25] or faciobrachial 
dystonic seizures [46]. In contrast, only two patients with 
intracellular antibodies (GAD65-4, -9) started as definite 
autoimmune encephalitis, both in the form of a limbic 
encephalitis (P < 0.0001). The maximum ASM-DDD 
were higher in the patients with intracellular antibodies 
(median 3.0, range 0–5.0) compared to those with sur-
face antibodies (median 1.3, range 0–6.8, P = 0.0003). 
The time from manifestation to antibody diagnosis was 
longer with intracellular antibodies (median 67, range 
0–333 months) compared to surface antibodies (median 
4, range 0–48 months, P = 0.0001). The following immu-
notherapies were administered (in brackets: number of 
treated patients): intravenous methylprednisolone (IVMP) 
or oral prednisolone (n = 37); intravenous immunoglobu-
lins (IVIG, n = 15); immunoadsorption (n = 22); plasma 
exchange (n = 1); azathioprine (n = 17); mycophenolate 
mofetil (n = 11); rituximab (n = 7); cyclophosphamide 
(n = 6); natalizumab (n = 2); basiliximab (n = 1). The 
groups did not differ in the number of immunotherapies 
(surface antibodies: median 3, range 1–6; intracellular 
antibodies: median 2.5, range 1–7; P = 0.62) or duration 
of immunotherapies (surface antibodies: median 3.8, range 
Fig. 1  Characteristics of the 
antibody-defined groups. 
ASM, anti-seizure medication; 
CASPR2, contactin-associated 
protein-2; DDD, defined daily 
dose; GAD65, glutamic acid 
decarboxylase 65 kDa; LGI1, 
leucine-rich glioma inactivated 
protein 1; NMDAR, N-methyl-
d-aspartate receptor. Lines and 
whiskers indicate medians and 
interquartile ranges
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0–12.5 years; intracellular antibodies: median 2.9, range 
0.4–13.8 years; P = 0.57).
Hippocampal sclerosis
Hippocampal sclerosis (HS), on magnetic resonance imaging 
(MRI), developed in patients with antibodies against LGI1 
(LGI1-2, -4, -5, -6, -7, -9, -11; 64%), GAD65 (GAD65-4, 
-7, -9, -13; 31%), and CASPR2 (CASPR2-4; 20%), but not 
with NMDAR antibodies. The patient with Ma2 antibod-
ies underwent an anteromedial temporal lobe resection ten 
years after disease onset; histologically, he had HS, ILAE 
type 3 with signs of chronic inflammation. HS had not been 
diagnosed preoperatively by MRI. A postoperative follow-up 
is not yet available. The following patients also underwent 
temporal lobe surgery, with histopathology congruent to 
MRI diagnoses: GAD65-4, HS (type 3); GAD65-5, no HS; 
GAD65-9, HS (type 3); GAD-13 HS (type 1). None of them 
became seizure-free.
Seizure‑freedom, ASM‑freedom
At most recent follow-up, the group with surface antibodies 
was superior regarding first and terminal seizure-freedom 
Fig. 2  Seizure and anti-seizure 
medication (ASM) freedom 
over time. Kaplan-Meier-
curves. Lines: censored cases. 
CASPR2, contactin-associated 
protein-2; GAD65, glutamic 
acid decarboxylase 65 kDa; 
LGI1, leucine-rich glioma 
inactivated protein 1; NMDAR, 
N-methyl-d-aspartate receptor
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(Table 2). Median duration of seizure-freedom at most 
recent follow-up was 4.4 years (range 1.8–7.0 years). The 
time to first and terminal seizure-freedom and to ASM-
freedom is depicted in Fig. 2 in the form of Kaplan–Meier 
curves. The patients with surface antibodies did better in all 
three parameters. Supplementary Table 2 shows the year-
wise proportions of seizure-free patients.
While the patients with intracellular antibodies only 
exceptionally became seizure-free, seizure frequency 
decreased over the years by ≤ 50% compared to onset in 8/13 
cases (in one case—GAD-7-no information about treatment 
during improvement was available). The seizure reduction 
was related to immunotherapy (GAD-12), ASM plus immu-
notherapy (GAD-4, -9 [plus epilepsy surgery], 10), ASM 
only (GAD-3, GAD-6) or no new intervention (GAD-1, -2).
Of note, 13/39 patients achieved terminal seizure-free-
dom after > 1 year (Supplementary Table 1); the maximum 
lapse was ten years (patient LGI1-9). This was partly due to 
relapses in the surface group (there were no relapses with 
intracellular antibodies). During relapses with seizures, 
semiology was the same as before where sufficient data were 
available. In 7/25 patients in the surface group, even the time 
to first seizure-freedom lasted more than one year; five of 
them continuously had seizures before they achieved first 
seizure-freedom (median 21 months, range 15–87). When 
patients became seizure-free, they had received additional 
immunotherapy but not always more intense ASM (Sup-
plementary Table 3).
Antibody titer courses
Titer courses started at different heights. The normalized 
and averaged serum and CSF antibody titers decreased over 
time in the patients with surface antibodies (exceptions on 
the individual level were only serum antibodies in patients 
CASPR2-5, -7,-8), but not in those with intracellular anti-
bodies (Fig. 3).
In many individuals, the titer courses corresponded with 
fluctuations in seizure frequency and mRS (NMDAR-1, -4 
in CSF; NMDAR-1, -4, -5, -6, LGI1-4, -6, -7, CASPR2-3, -7 
in serum, partly in the absence of sufficient CSF studies). An 
elevation in serum LGI1 antibodies heralded the first relapse 
in patient LGI1-4. In other instances, titers increased again 
without clinical deterioration (LGI1-2, CASPR2-1, -4, -6, 
-8, all in serum). Occasionally, serum titers kept decreas-
ing after seizures and elevated mRS had already remitted 
(LGI1-3, LGI1-11, CASPR2-2, all in serum). Elevated CSF 
antibodies became unmeasurable in only 2/15 cases with 
surface antibodies (both LGI1) and 3/13 with intracellular 
antibodies (all GAD65). Serum titers became undetectable 
in 7/11 cases with antibodies against LGI1, 2/5 against the 
NMDAR, 0/8 against CASPR2, 0/13 against GAD65, and 
0/1 against Ma2. Apheresis had the strongest immediate 
effect on titers (NMDAR-2, CASPR2-3, -4 in CSF; LGI1-1, 
-8, -10, in serum). However, titers often rose again after such 
interventions, especially if there was insufficient steroid or 
immunosuppressive treatment after the apheresis (NMDAR-
1, -3, -4, -5, LGI1-2, -4, -5, -11, CASPR2-1, -3, -4, -7, -8, all 
in serum, an exception being LGI1-10).
In most patients with intracellular antibodies, serum 
and CSF titers did not decrease in the long term. Periods 
of intense immunotherapy could lower the titers, but they 
eventually increased again (GAD65-1, -5, 6, -8, 9, 10 in 
serum; GAD65-2, -3, -10 in serum and CSF). The case of 
GAD65-12 was exceptional and spectacular. This patient, 
with recent manifestation of diabetes mellitus type I and 
Fig. 3  Courses of antibody titers in the cerebrospinal fluid (CSF, 
upper row, blue) and serum (lower row, red) during the first eight 
years after disease onset. The dots show all individual values, 
expressed as a percent of the individual’s highest titer. The blue dots 
in G and H are those of the patient with Ma2 antibodies. The lines are 
smoothed averages (see the Methods section)
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Hashimoto thyroiditis, had her first seizure at age 15 years. 
There were no other features of limbic encephalitis. GAD65 
antibodies were detected two weeks later, and she received 
her first monthly IVMP pulse with another 4 weeks later. Six 
pulses, five times of 1 g each, were administered. She never 
received ASM. Seizure frequency reduced. She had her last 
seizure 2.5 months after the first IVMP pulse. Her titers were 
strongly reduced.
Discussion
This retrospective study examined patients with neural 
autoantibodies and seizures and—as the most interesting 
novelty—analyzed long-term courses ≥ 3 years (median 
7.5 years). Patients with surface antibodies achieved first 
and terminal seizure-freedom in 88% and 80% of cases. 
This is the same proportion as the 81% of patients with a 
seizure in close temporal association with a documented 
brain insult and without subsequent unprovoked seizures 
over ten years in a classical study [28]. These seizures were 
defined by the ILAE as “acute symptomatic” [1]. In con-
trast, only one patient with intracellular antibodies (7%) 
reached this favorable outcome (Table 2). The remaining 
rate of 93% of patients with subsequent unprovoked sei-
zures lies in the range of the > 60% relapse risk that defines 
epilepsy according to the ILAE [22]. Patients with surface 
antibodies had lower maximum ASM-DDD (Fig. 1b), and 
ASM were discontinued earlier (Fig. 2a vs. 2E). Patients 
could become seizure-free after more than one year, always 
with additional immunotherapies, but not necessarily with 
ASM-DDD increases; in fact, the patients LGI1-2, -4, -11 
became seizure-free while they were not taking any ASM 
(Supplementary Table 3). These observations correlate 
with the decreasing titers of surface but not of intracellular 
antibodies (Fig. 3). Thus, autoimmune encephalitides with 
NMDAR, LGI1, or CASPR2 antibodies are ictogenic but not 
usually epileptogenic. They force the brain to seize as long 
as the antibodies are present in a sufficiently high concen-
tration but they rarely transform the central nervous system 
in a way that it generates recurrent unprovoked seizures, 
i.e., the observed seizures are but symptoms of a transient 
external disease process [1]. Intracellular antibodies, on the 
other hand, seem to be markers of a profound, enduring, and 
ASM-resistant propensity to generate recurrent unprovoked 
epileptic seizures, i.e., epilepsy [23]. These patients even 
respond poorly to epilepsy surgery, here and in the literature 
[8]. Out data thereby confirm previous hypotheses [24, 44]. 
They refine Geis’ and colleagues’ preliminary suggestion 
that seizures for more than one year in patients with autoim-
mune encephalitides should lead to the diagnosis of epilepsy. 
According to our data, it can take up to seven years before 
continuously recurrent seizures secondary to an autoimmune 
encephalitis subside.
The term acute symptomatic seizures may appear 
stretched in such long-term courses. These are, however, 
exceptional in this sample. Whereas the demographic data 
of our cases were as expected from the antibody types, the 
long clinical follow-up was special. Delays to seizure-free-
dom were much longer in our patients than in a previous 
unselected series that reported on a median lag to seizure 
remission within a month after start of immunotherapy 
(interquartile range 0.3–2.4 months) [13]. Our long-term 
follow-up sample demonstrates the concept at its extremes. 
At the same time, it shows that terminal seizure-freedom 
in such cases was long-lasting and stable (≥ 21 months of 
terminal seizure-free follow-up).
An epilepsy diagnosis results in marked driving restric-
tions and limited professional abilities. We suggest that 
patients with seizures secondary to autoimmune encepha-
litides and antibodies against NMDAR, LGI1, or CASPR2 
should be individually evaluated for social restrictions, as 
suggested by a UK guideline that mentions “limbic encepha-
litis associated with seizures” together with acute encepha-
litides and meningitis, apart from chronic epilepsy [16]. 
Congruently, a review article reported a low long-term risk 
(< 15%) to develop epilepsy after encephalitides associated 
with surface antibodies [43].
The time to diagnosis of surface antibodies was shorter 
compared to intracellular antibodies (NMDAR < LGI1 < C
ASPR <  < GAD65, Table 1 and Fig. 1d). This phenomenon 
is probably due to the subacute start in the autoimmune 
Table 2  Outcome at most recent follow-up: First and terminal seizure-freedom and anti-seizure medication (ASM) freedom
n.s. not significant
First seizure-freedom Terminal seizure-freedom ASM-freedom Total
Seizure-free Not seizure-free Seizure-free Not seizure-free ASM stopped or 
never given
ASM ongoing
Surface antibodies 22 (88%) 3 (12%) 20 (80%) 5 (20%) 11 (44%) 14 (56%) 25
Intracellular antibodies 1 (7%) 13 (93%) 1 (7%) 13 (93%) 1 (7%) 13 (93%) 14
Sums 23 16 21 18 12 27 39
P  < 0.0001 < 0.0001 0.0283 (n.s.)
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encephalitides with surface antibodies [13], which is only 
occasionally noted in patients with GAD65 antibodies and 
a limbic encephalitis at onset [37].
Individual titer courses of surface antibodies, to some 
extent, moved in parallel to the clinical courses. In some 
cases, antibodies increased again despite clinical recovery, 
or antibodies fell more slowly than patients recovered—
especially CASPR2 antibodies. Antibody titers, thus, did 
not in general predict the immediately subsequent clinical 
course. Titers of intracellular antibodies remained high or 
increased again after transient reduction by intense immu-
notherapies. Titer courses confirmed chronicity but were 
otherwise not clinically informative.
HS occurred at similar frequencies in patients with 
surface and intracellular antibodies. It occurred most fre-
quently with LGI1 antibodies (64%), despite the favorable 
seizure outcome in this group. This proportion is in line 
with existing figures of 41% [49] or 50% [21]. Other studies 
reported hippocampal abnormalities with NMDAR antibod-
ies in < 10%, [36, 37] again congruent with our data (0%) 
[20, 30]. CASPR2 antibodies (20%) and GAD65 antibodies 
(31%) were between those values, again consistent with the 
literature reporting on 20–24% [32, 48] and 33–62% [17, 
35] of cases, respectively, having hippocampal lesions or 
atrophy/sclerosis. Hence, in patients with neural antibodies, 
obvious hippocampal damage is neither necessary nor suf-
ficient for the development of epilepsy. A caveat comes from 
the case with Ma2 antibodies, whose HS was only diagnosed 
under microscope. The true frequency of structural epilepto-
genic damage might be underestimated in this series.
Immunotherapy is the most relevant treatment in seizures 
secondary to autoimmune encephalitis. Recurrent seizures 
and cognitive decline may be prevented if immunotherapy 
is applied early in patients with surface antibodies [7, 13, 
29, 46, 47] but not with intracellular antibodies [7, 36]. 
This hypothesis is confirmed by the present series. The 
first-line and second-line therapy concept derived from the 
retrospective analysis of treatment courses in anti-NMDAR 
encephalitis [12] has been widely adopted in autoimmune 
encephalitides with different surface antibodies [7, 33]. It 
can be recognized in cases of the present series, including 
those with anti-NMDAR encephalitis who only responded 
to second-line therapy with rituximab. Most patients had 
several immunological treatment approaches. Due to the ret-
rospective and uncontrolled documentation of combination 
therapies, we did not attempt to disentangle the contribution 
of single interventions.
Patients with intracellular antigens did not benefit 
from immunotherapy, except for one patient (GAD65-12) 
who became seizure-free under IVMP pulses starting six 
weeks after disease onset. A similar case has recently been 
described [14]. In contrast, immunotherapy does not stop 
seizures in chronic patients with GAD65 antibodies [36].
Plasmapheresis or immunoadsorption had an immediate 
but no long-lasting effect on antibody courses. A special 
case was patient LGI1-10, who stopped having seizures 
and had reduced antibody titers after only one sequence of 
immunoadsorption.
ASMs are mostly considered as an add-on-therapy for 
patients with autoimmune encephalitides with surface 
antibodies [18], but usually not as a stand-alone or long-
term treatment [13, 34]. They usually do not have a strong 
effect unless applied together with immunotherapy [19, 
46]. This can also be observed in our sample: Only 1/11 
cases, in which ASM was discontinued, had a seizure relapse 
(NMDAR-1, latency 2 days, 14 months after disease onset; 
immunotherapy had been stopped 3.5 months before, and 
there were still NMDAR antibodies in serum and CSF). Vice 
versa, only 1/3 cases with introduction of an ASM without 
a parallel intensification or introduction of immunotherapy 
experienced a reduction in seizure frequency (NMDAR-5, 
four years after onset); in the other two instances, mere intro-
duction of ASM was without effect on seizure frequency 
(LGI1-7, 4.5 years after onset; CASPR2-4, 3.5 years after 
onset, both with HS).
This study has limitations. First, we documented and 
rated data retrospectively, a process that has inherent prob-
lems. Second, the study group is biased toward difficult-to-
treat patients. Third, patients were treated by various ASM 
and immunotherapies in different orders and combinations. 
Fourth, the patients did not systematically undergo pro-
longed video-EEG monitoring to capture unnoticed or una-
ware seizures [45]. Fifth, the data do not directly determine 
ante hoc in an individual patient with surface antibodies 
when to diagnose an “epilepsy.” One may tentatively suggest 
to diagnose epilepsy if seizures go on for more than one year 
even though the antibodies in serum (LGI1 or CASPR2) or 
CSF (NMDAR) [27] have gone down by more than three or 
more than titer levels compared to onset, especially (but not 
necessarily), if potentially epileptogenic atrophic brain dam-
age is evident. This phenomenon seems to be the case for 
these four patients: LGI1-7, CASPR2-4 (both with HS), and 
NMDAR-3, -5 (without structural damage). After symptom 
control, immunotherapies could be discontinued without 
early deteriorations, regardless of titers (NMDAR-6, LGI1-
1, -3, -5, -7 [epilepsy persisted], -8, -9, 10, CASPR2-1, -4 
[epilepsy persisted],-5, -6; two of these patients relapsed 
after > 1 year: NMDAR-6; LGI1-9). ASM contributed less 
than immunotherapies; they could be discontinued with-
out provoking a seizure relapse (the only exception being 
NMDAR-1).
In conclusion, this study shows, on a group level, that 
patients with autoimmune encephalitides and surface anti-
bodies have acute symptomatic seizures that do usually not 
require long-term immunological or ASM therapy or social 
restrictions. In contrast, patients with intracellular antibodies 
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and seizures—if not treated early on—develop epilepsy. 
Antibody titers can partially help to interpret the clinical 
courses, especially on the group level.
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